Sandoz

Recently, our Chief Scientific Officer Claire D'Abreu-Hayling joined a panel of women in pharma to discuss the impact of Brexit on drug development at Women of Color in Pharma (WOCIP)'s Global Conversations and Connections event earlier this week. 💊    Drawing on her own experiences of living and working in the UK, Claire shared her insights on the evolving landscape of drug development. The panel sparked some thought-provoking discussions on the positives and challenges the UK faces after leaving the EU.     Topics included:  ☑️ Regulation of off-patent medicines, which currently fill four out of five of all NHS prescriptions and deliver savings of around £16 billion per year to the NHS  🔬 The impact on diversity and science in the UK, where it’s evident that the world-class science and research capabilities remain       #Sandoz #DrugDevelopment #Brexit 

This week at Sandoz, we discussed how we can continue to build upon our culture to create a truly diverse and inclusive environment for the LGBTQI community and allies. Employees around the world joined our global Pride webcast, ‘Leading by Example to Spark Progress’. We heard from colleagues on how they are engaging in LGBTQI initiatives, and some of our senior leaders shared their personal experiences and recommendations. By coming together to learn more, listen, and grow in our understanding of the challenges faced by the LGBTQI community, we can create meaningful change. Check out this video from around the globe to see how colorful Sandoz looked in June. And while Pride month is coming to a close, it doesn’t stop there. We are committed to embracing the spirit of Pride and LGBTQI inclusion in all that we do, every day, from equipping our employees with clear guidance in our Transgender Identity and Allyship Guides, to providing safe spaces to share and learn from experiences. #SandozPride #PrideMonth

We recently brought together 31 patient advocacy leaders in Munich to discuss crucial issues impacting access to medicines. With a focus on biosimilars and generics, our goal was to identify key policy issues, address knowledge gaps, and drive expanded access through collaboration. Many thanks to the co-chairs of the Forum Zorana Maravic and Daneen Sekoni and all the participants for the meaningful conversations that transcended borders. Stay tuned for updates on the actionable steps that will emerge from these important discussions. Together, we can make a difference! 💙 #MakingAccessHappen #Biosimilars #Generics #Collaboration #GlobalHealthcare

Throughout the year at Sandoz we celebrate what makes us unique, and Pride month is an opportunity to celebrate the LGBTQI community and recognize the strength, resilience and progress that comes from standing together in unity. By fostering a sense of community among our LGBTQI employees and allies, we can empower everyone to be their authentic selves, to leverage our diverse perspectives to make an impact on our patient mission and collectively create positive change. Together, we can amplify voices, advocate for equality, and build a more inclusive society. Thanks to Paul Walz for sharing his experience of working at Sandoz. Click to learn more: https://lnkd.in/dbxSxAKP #SandozPride #PrideMonth #Pride #SandozLife

We support stronger healthcare systems by providing affordable medicines. In 2023, our products alone delivered over USD 18 billion in savings to US and EU healthcare systems by providing high quality generic and biosimilar medicines to patients.   As the global population keeps growing and ageing, placing an ever-increasing financial strain on healthcare systems, we are democratizing biologic medicines by increasing their availability and affordability, and by educating healthcare professionals on their use. Today, we already market 10 successful biosimilars with an additional 24 in the pipeline.   #Generics #Biosimilars #PatientAccess

According to the WHO, more than 600,000 people die every year as a result of HIV/AIDS because they didn’t know they had HIV or because they started treatment too late. Latin America is among the regions most affected, where annual numbers of new HIV cases have increased by 8% from 2010 to 2022. We recognize the importance of prevention, education, and accurate information about HIV. In September 2023, we launched the ‘PrEPárate contra el VIH’ campaign to help raise awareness of HIV in Mexico. Through in-person events and social media, the local community in Mexico and beyond can access reliable information from healthcare experts in a simple and digestible way. Learn more: https://lnkd.in/gcc9CKiQ #SandozPride #HIVPrEP #PrideMonth

Through our presence in more than 100 markets we already provide over 800 million patient treatments per year, freeing up resources for healthcare systems and generating a positive social impact estimated at USD 400 billion. To continue providing equal access to quality-assured generic and biosimilar medicines to more patients worldwide, collaboration with organizations like IGBA - International Generic and Biosimilar medicines Association is key.

Rebecca Guntern, Region Europe President at Sandoz, is back from Medicines for Europe Annual Conference, celebrating their remarkable 30th anniversary of advocating for better healthcare policies in Europe. She reflects on the insights gained from the conference, where industry leaders gathered to explore the past three decades of progress and project their visions for the next 20-30 years.

Generic and biosimilar medicines account for 70% of the medicines dispensed in Europe, so it’s critical that the policies and legal frameworks governing the pharmaceutical industry put patients and healthcare systems first to ensure access to affordable medicines at the earliest possible date. The Medicines for Europe team put on another excellent edition of its Legal Affairs Conference in Ireland earlier this week and Karen Gallagher of Pinsent Masons did a great job moderating our General Counsel panel on how a reshaping world is reshaping our industry. Thank you to fellow panelists Agnieszka Deeg-Tyburska, Mark Ferguson, and Barbara Majcen for their excellent insights. We all have a role to play in making early access happen and Sandoz is looking forward to working with policymakers, regulators, reference medicines companies, and other stakeholders to address the challenges we are all currently facing.